News
Our Story
Over the Years
![](http://gennisium.com/wp-content/uploads/2020/09/Ellipse-1-1.png)
November 2020
Exclusive licence agreement
(Europe)
Gennisium grants exclusive licence agreement to Mercapharm for Gencebok® in Poland
![](http://gennisium.com/wp-content/uploads/2020/09/Ellipse-1-1.png)
October 2020
Exclusive licence agreement
(Asia)
Gennisium grants exclusive licence agreement to AxxessBio (Singapore) for Gencebok® in South-East Asian countries
![](http://gennisium.com/wp-content/uploads/2020/09/Ellipse-1-1.png)
October 2020
Exclusive licence agreement
(Europe)
Gennisium grants exclusive licence agreement to Nordic Prime (Denmark) for Gencebok® in the Nordics
![](http://gennisium.com/wp-content/uploads/2020/09/Ellipse-1-1.png)
October 2020
Exclusive licence agreement
(LATAM)
Gennisium grants exclusive licence agreement to Global Farma (Guatemala) for Gencebok® in Central America, Caribbean and Venezuela
![](http://gennisium.com/wp-content/uploads/2020/09/Ellipse-1-1.png)
August 2020
European Marketing Autorisation
European Commission grants Marketing Autorisation to Gencebok®, further to positive opinion delivered by EMA
![](http://gennisium.com/wp-content/uploads/2020/09/Ellipse-1-1.png)
JUNE 2020
Positive opinion (EMA)
CHMP grants positive opinion to Gencebok®, 10 mg/ml solution for infusion (1 ml ampoule), for i.v. and oral use
![](http://gennisium.com/wp-content/uploads/2020/09/Ellipse-1-1.png)
MAY 2020
Exclusive licence agreement
(Oceania)
Gennisium grants exclusive licence agreement to Reach-Pharma (Australia) for Gencebok® in Australia, New-Zealand and Papua-New Guinea
![](http://gennisium.com/wp-content/uploads/2020/09/Ellipse-1-1.png)
April 2020
Exclusive Licence Agreement
(LATAM)
Gennisium expands its presence in the most important markets in Latin America, Mexico and Brazil, in granting exclusive promotion rights to Moksha8 for Gencebok®
![](http://gennisium.com/wp-content/uploads/2020/09/Ellipse-1-1.png)
November 2019
Incubated by the French public company Paris Biotech Santé
Gennisium is incubated by the French public company Paris Biotech Santé, which supports start-ups specialised in Health area and is located at Paris
![](http://gennisium.com/wp-content/uploads/2020/09/Ellipse-1-1.png)
OCTOBER 2019
First European marketing authorization application submitted
First European marketing authorization application submitted by Gennisium to EMA for caffeine citrate (Gencebok® ; centralised procedure – hybrid application). Caffeine citrate is indicated in premature newborns for the treatment of primary apnoea
![](http://gennisium.com/wp-content/uploads/2020/09/Ellipse-1-1.png)
June 2018
Founded
Incorporation of Gennisium